DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

King DS, Sharp RL, Vukovich MD, et al. Effect of oral
androstenedione on serum testosterone and adaptation to
resistance training in young men: a randomized controlled
trial. JAMA, 1999, 28:2020–2028.
MacDonald PC, Madden JD, Brenner PF, et al. Origin of estrogen
in normal men and in women with testicular feminization.
J Clin Endocrinol Metab, 1979, 49:905–917.
McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride
on the risk of acute urinary retention and the need for
surgical treatment among men with benign prostatic hyperplasia.
Finasteride Long-Term Efficacy and Safety Study Group.
N Engl J Med, 1998, 338:557–563.
McPhaul MJ, Griffin JE. Male pseudohermaphroditism caused
by mutations of the human androgen receptor. J Clin
Endocrinol Metab, 1999, 84:3435–3441
Miller KK, Biller BM, Beauregard C, et al. Effects of testosterone
replacement in androgen-deficient women with hypopituitarism:
A randomized, double-blind, placebo-controlled
study. J Clin Endocrinol Metab, 2006, 91:1683–1690.
Molla M, Delcher A, Sunyaev S, Cantor C, Kasif S. Triplet
repeat length bias and variation in the human transcriptome.
Proc Natl Acad Sci USA, 2009, 106:17095–17100.
Montie H, Cho M, Holder L, et al. Cytoplasmic retention of
polyglutamine-expanded androgen receptor ameliorates disease
via autophagy in a mouse model of spinal and bulbar
muscular atrophy. Hum Mol Genet, 2009, 18:1937–1950.
Murray MP, Gardner GM, Mollinger LA, et al. Strength of isometric
and isokinetic contractions: Knee muscles of men aged
20 to 86. Phys Ther, 1980, 60:412–419.
Narayanan R, Mohler ML, Bohl CE, et al. Selective androgen
receptor modulators in preclinical and clinical development.
Nucl Recept Signal, 2008, 6:e010.
Rochira V, Carani C. Aromatase deficiency in men: a clinical
perspective. Nat Rev Endocrinol, 2009, 5: 559–568.
Schubert M, Minnemann T, Hubler D, et al. Intramuscular testosterone
undecanoate: Pharmacokinetic aspects of a novel testosterone
formulation during long-term treatment of men with
hypogonadism. J Clin Endocrinol Metab, 2004, 89:5429–5434.
Schulze JJ, Lorentzon M, Ohlsson C, et al. Genetic aspects of
epitestosterone formation and androgen disposition: Influence
of polymorphisms in CYP17 and UGT2B enzymes.
Pharmacogenet Genomics, 2008, 18:477–485.
Smith CL, O’Malley BW. Coregulator function: A key to understanding
tissue specificity of selective receptor modulators.
Endocr Rev, 2004, 25:45–71.
Smith EP, Boyd J, Frank GR. Estrogen resistance caused by a
mutation in the estrogen-receptor gene in a man. N Engl J
Med, 1994, 331:1056–1061.
Snyder PJ, Lawrence DA. Treatment of male hypogonadism with
testosterone enanthate. J Clin Endocrinol Metab, 1980,
51:1535–1539.
Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone
treatment on bone mineral density in men over 65 years of age.
J Clin Endocrinol Metab, 1999a, 84:1966–1972.
Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone
treatment on body composition and muscle strength in men
over 65 years of age. J Clin Endocrinol Metab, 1999b,
84:2647–2653.
Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone
replacement in hypogonadal men. J Clin Endocrinol Metab,
2000, 85:2670–2677.
Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics
of transdermal testosterone gel in hypogonadal
men. J Clin Endocrinol Metab, 2000, 85:4500–4510. Taplin
ME, Balk SP. Androgen receptor: A key molecule in the progression
of prostate cancer to hormone independence. J Cell
Biochem, 2004, 91:483–490.
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of
finasteride on the development of prostate cancer. N Engl J
Med, 2003, 349:215–224.
Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter,
open label, randomized study of abarelix versus leuprolide
plus daily antiandrogen in men with prostate cancer.
J Urol, 2002, 167:1670–1674.
Venturoli S, Marescalchi O, Colombo FM, et al. A prospective
randomized trial comparing low dose flutamide, finasteride,
ketoconazole, and cyproterone acetate-estrogen regimens in
the treatment of hirsutism. J Clin Endocrinol Metab, 1999,
84:1304–1310.
Walcott J, Merry D. Trinucleotide repeat disease. The androgen
receptor in spinal and bulbar muscular atrophy. Vitam Horm,
2002, 65:127–147.
Wilson JD. The pathogenesis of benign prostatic hyperplasia.
Am J Med, 1980, 68:745–756.
Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase
2 deficiency. Endocr Rev, 1993, 14:577–593.
1207
CHAPTER 41
ANDROGENS